Yasuo Terauchi
Yokohama, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 280 publications
Case Report: a family presenting with β-adrenergic/vasopressin-responsive bilateral macronodular adrenal disease with an ARMC5 mutation treated with metyrapone monotherapy for more than 5 years.
Journal: Frontiers in endocrinology
Published: April 10, 2026
Metformin suppresses β-cell apoptosis under ER stress by inhibiting protein translation.
Journal: Metabolism: clinical and experimental
Published: January 20, 2026
Impact of a Transparent Easy Nudge-Based Notification on the Follow-Up Examination Behaviors in Japanese Workers: A Controlled Experiment.
Journal: JMA journal
Published: December 11, 2025
Efficacy of MiniMed™ 780G® on glucose management, sleep quality, and psychological aspects in persons with type 1 diabetes treated with MiniMed™ 770G®: A 3-month prospective single-center observational study.
Journal: Journal of diabetes investigation
Published: September 08, 2025
A Retrospective Analysis of the Clinical Characteristics and Treatment Patterns Among Individuals with Diabetes Receiving Insulin Therapy in Japan: The Insulin JP2DB Study.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: August 08, 2025
Cardiovascular Risk Reduction With Tirzepatide, a Dual GIP/GLP-1 Agonist, in Patients With Type 2 Diabetes Mellitus.
Journal: Journal of lipid and atherosclerosis
Published: July 14, 2025
Regulatory Roles of IGF2R in Insulin Secretion and Adaptive β-Cell Proliferation.
Journal: Diabetes
Published: March 03, 2025
A multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice (PIONEER REAL Japan): Subgroup analyses.
Journal: Journal of diabetes investigation
Published: February 11, 2025
Imeglimin suppresses glucagon secretion and induces a loss of α cell identity.
Journal: Cell reports. Medicine
Published: December 10, 2024
Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial.
Journal: The lancet. Diabetes & endocrinology
Published: December 06, 2024
Safety of iGlarLixi in Japanese People with Type 2 Diabetes: A Post-marketing Database Study.
Journal: Advances in therapy
Published: November 05, 2024
Author Correction: Effectiveness of DialBetesPlus, a self-management support system for diabetic kidney disease: Randomized controlled trial.
Journal: NPJ digital medicine
Published: June 15, 2024
Last Updated: 09/26/2026